ArticleCureus2026
Factors Associated With Discordance Between the Activated Partial Thromboplastin Time and Anti-factor Xa Activity During Extracorporeal Membrane Oxygenation: A Retrospective Cohort Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReliable anticoagulation monitoring during extracorporeal membrane oxygenation (ECMO) guides the balance between bleeding and thrombosis, yet the activated partial thromboplastin time (aPTT) and anti-factor Xa (anti-Xa) activity frequently disagree, and the factors associated with discordance are poorly defined. We sought to determine the prevalence of aPTT and anti-Xa discordance during unfractionated heparin anticoagulation on ECMO, to identify associated factors, and to characterize clinician response. METHODOLOGY: We conducted a retrospective cohort study at a single ECMO center from 2019 to 2025, including neonates, children, and adults anticoagulated with heparin. aPTT and anti-Xa values drawn within six hours of each other were paired and classified as concordant or discordant. Generalized linear mixed-effects models with a random intercept for patient accounted for repeated measurements within patients.
resultsA total of 89 ECMO runs contributed 1,252 paired observations. Discordance occurred in 59.1% (740 of 1,252) of pairs, and the correlation between assays was moderate (Pearson R=0.41). Discordance was most frequent in neonates (464 of 671, 69.2%) compared with older children (32 of 66, 48.5%) and adults (244 of 515, 47.4%; unadjusted p<0.001). In univariate analysis, discordance was associated with lower weight and lower fibrinogen and with higher anti-Xa, aPTT, prothrombin time, and heparin dose. In mixed-effects models, a higher heparin infusion dose at the time of paired sampling was the only factor independently associated with discordance (adjusted odds ratio: 1.14; 95% CI: 1.07-1.22; p<0.001). Clinicians adjusted heparin after 396 of 740 discordant pairs (53.5%); changes aligned with anti-Xa in 329 of 740 (44.5%), with aPTT in 238 of 740 (32.2%), and with neither assay in 173 of 740 (23.4%). Anti-Xa-aligned changes were associated with a higher baseline heparin dose (adjusted odds ratio: 1.10; 95% CI: 1.02-1.19), whereas aPTT-aligned changes were associated with a higher aPTT (adjusted odds ratio: 1.04; 95% CI: 1.01-1.06) and higher fibrinogen (adjusted odds ratio: 1.01; 95% CI: 1.00-1.01).
conclusionsDiscordance between aPTT and anti-Xa is common during ECMO and varies by age group. Higher heparin infusion dose was independently associated with discordance, and clinician responses to discordant pairs were heterogeneous, highlighting persistent uncertainty in managing discordant anticoagulation assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.